Clinical data | |
---|---|
Trade names | Beleodaq |
Other names | PXD101 |
AHFS/ Drugs.com | beleodaq |
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (IV) |
Protein binding | 92.9–95.8% [1] |
Metabolism | UGT1A1 |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H14N2O4S |
Molar mass | 318.35 g·mol−1 |
3D model ( JSmol) | |
| |
|
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. [2]
It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma. [3]
In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. [4] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging. [5] Belinostat has been granted orphan drug and fast track designation by the FDA, [6] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014. [3] It is not approved in Europe as of August 2014 [update]. [7]
The approved pharmaceutical formulation is given intravenously. [8]: 180 Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele. [8]: 179 and 181